Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb
Produktgrößen
100µg
£768,00
12-2002-100UG
Über dieses Produkt
- SKU:
- 12-2002
- Klonalität:
- Monoclonal
- Weitere Details:
- Ixekizumab/ Anti-IL-17A (Taltz) is a humanized IgG4 biosimilar monoclonal antibody expressed by mammalian cell lines that block the biological activity of IL-17A. IL-17A is a pro-inflammatory cytokine that triggers immune cells like neutrophils; lymphocytes; macrophages; monocytes; natural killer (NK) cells; and B cells that play essential roles in innate and adaptive immune responses. IL-17A binds IL17RA-IL17RC heterodimeric receptor complex to activate TRAF6 and NF-kappaB pathway; leading to pro inflammatory cytokines and chemokines gene expression. The Ixekizumab biosimilar developed by Abeomics is a high-quality research grade biosimilar and is not to be used for therapeutic or diagnostic procedures for humans and animals.
- Isotyp:
- IgG4
- Aufreinigung:
- Purified from cell culture supernatant by affinity chromatography
- Reaktivitäten:
- Human
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- Store at -20[o]C to -80[o]C (Avoid repeated freezing and thawing).
- Hersteller:
- Abeomics
- Typ:
- Antibodies:Monoclonal Antibody
- Datenblatt des Herstellers:12-2002 Taltz 5ug Coomassie 031423.jpg